Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

WCLC 2022 | Differences of response to IO +/- chemotherapy or IO in NSCLC depending on PD-L1 expression levels

Filiz Oezkan, MD, University Hospital Essen, Essen, Germany, provides an overview of her presentation at the IASLC 2022 World Conference on Lung Cancer congress, commenting on the evolution of chemotherapies to the combination of chemotherapies plus immunotherapies. Immunotherapies with or without combination with either chemotherapy or additional immunotherapies have recently been moved to the first-line of treatment of patients with stage IV non-small cell lung cancer (NSCLC). Dr Oezkan compared the differences in response to these treatments depending on PD-L1 expression levels. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.